Rationally select the timing and treatment method of central serous chorioretinopathy
10.3760/cma.j.cn511434-20230224-00088
- VernacularTitle:合理选择中心性浆液性脉络膜视网膜病变的治疗时机及治疗方法
- Author:
Mingwei ZHAO
1
Author Information
1. 北京大学人民医院眼科眼病与视光医学研究所视网膜脉络膜疾病诊治研究北京市重点实验室北京大学医学部眼视光学院，北京 100044
- Keywords:
Central serous chorioretinopathy;
Laser photocoagulation;
Subthreshold micropulse laser;
Photodynamic therapy;
Editorial
- From:
Chinese Journal of Ocular Fundus Diseases
2023;39(4):271-274
- CountryChina
- Language:Chinese
-
Abstract:
Central serous chorioretinopathy (CSC) is a common macular disease, mainly manifested as a plasma detachment of the macula. Photodynamic therapy (PDT) is an effective treatment for CSC, but with the shortage of the photosensitizer Verteporfin, the effective treatment of CSC has become a common concern for ophthalmologists. In this paper, based on the latest research results on the relationship between the changes in the thickness of the outer nuclear layer and the natural course of the disease and PDT therapy, we propose that patients with CSC should receive effective treatment as early as possible to prevent irreversible damage to visual function due to the thinning of the outer nuclear layer. In addition to PDT, it is recommended that laser photocoagulation or subthreshold micropulse laser treatment of the leaking spot should be considered first, depending on the presence of the leaking spot and its location in relation to the macula center. Anti-vascular endothelial growth factor therapy can be considered if there is a combination of choroidal neovascularization and/or polypoidal choroidal vasculopathy. Other treatments that have not been demonstrated to be effective in evidence-based medicine are not recommended.
